WEE1 and acute myeloid leukemia: In this study, we also observed multiple kinase inhibitors targeting a variety of kinases involved in mitosis including alisertib (aurora A; active 4/8), barasertib (aurora B; active 3/8), MK-1775 (Wee1; active 7/8) rigosertib (polo-like kinase; active 7/8), and volasertib (polo-like kinase; active 7/8) and motor protein inhibitor ARRY-520 (Eg5; active 3/8) to have anti-leukemic activity, highlighting a vulnerability inherent to AML, among other cancers (Supplementary Data 2).